Sosei Heptares and Captor Therapeutics Enter Strategic Technology Collaboration Focused on Targeted GPCR Degradation as Novel Approach for Drug Design
Sosei Heptares and Captor Therapeutics Enter Strategic Technology Collaboration Focused on Targeted GPCR Degradation as Novel Approach for Drug Design - Program focused on identifying small molecules that target a GPCR for degradation as potential therapeutic agents for gastrointestinal disorders - Unique combination of novel technologies to enhance GPCR drug discovery and expand capabilities into wider drug target universe News provided by Share this article Share this article TOKYO and CAMBRIDGE, England, Dec. 22, 2020 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565), a ...
Source: prnewswire.com